<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19900">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766011</url>
  </required_header>
  <id_info>
    <org_study_id>AL01</org_study_id>
    <nct_id>NCT01766011</nct_id>
  </id_info>
  <brief_title>Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital</brief_title>
  <official_title>Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess overall growth of preterm infants fed a reformulated
      preterm infant formula during hospitalization.  All study products meet levels of nutrients
      for the infant population as specified in the Infant Formula Act and all subsequent
      amendments.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Weight gain per day</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>weight gain per day (g/kg/d)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Growth, change in length</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Stool Questionnaire</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gastro-intestinal Tolerance; Presence of bloody, watery, hard or black stools will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>SDAY 1, 15, and 29 or hospital discharge (whichever comes first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood biochemistries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Growth, change in head circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Feeding Questionnaire</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gastro-Intestinal Tolerance; Cause for withholding feedings will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any periods of nil per os (NPO)</measure>
    <time_frame>Study Day (SDAY) 1   to SDAY 29, or hospital discharge, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gastro-Intestinal Tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorus</measure>
    <time_frame>SDAY 1, 15, and 29 or hospital discharge (whichever comes first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood biochemistries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase</measure>
    <time_frame>SDAY 1, 15, and 29 or hospital discharge (whichever comes first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood biochemistries</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pre-term Infants</condition>
  <arm_group>
    <arm_group_label>study pre-term formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>study pre-term formula</intervention_name>
    <description>24 kcal/fl oz pre-term formula for in-hospital use</description>
    <arm_group_label>study pre-term formula</arm_group_label>
    <other_name>Similac Special Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects eligible for study participation will satisfy the following criteria:

               -  Birth weight between 1000g -1800g

               -  Less than or equal to 34 weeks and 0 days gestational age at birth

               -  Appropriate for gestational age (AGA)

               -  Singleton or twin births

               -  Infant is 21 days of age or less

        Exclusion Criteria:

          -  Infants with the following conditions prior to and/or at the time of study product
             initiation are not eligible for entry into the study:

               -  Expected to be transferred to another facility within 14 days

               -  Serious congenital abnormalities that may affect growth and development

               -  Intubated for ventilation at the time of study product initiation

               -  Grade III or IV  periventricular/intraventricular hemorrhage (PVH/IVH)

               -  Maternal incapacity, maternal drug or alcohol abuse during pregnancy or current
                  abuse, or maternal treatment consistent with human immunodeficiency virus
                  therapy

               -  Infant has a history of major surgery

               -  Asphyxia defined as progressive hypoxemia and hypercapnia with significant
                  metabolic acidemia

               -  Confirmed necrotizing enterocolitis or confirmed sepsis

               -  Current use or planned use of probiotics

               -  Participation in another study that has not been approved
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bridget Barrett Reis, PhD, RD, LD</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RD</last_name>
    <phone>614 624 5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bobbie Swearengin, RN</last_name>
    <phone>614 624 7182</phone>
    <email>bobbie.swearengin@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama - Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fabien Eyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barry Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Children's Hospital Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lance Parton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sharon Groh-Wargo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Killian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wheaton Franciscan Healthcare-St. Joseph</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeffery Garland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 25, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
